

CITATION REPORT

List of articles citing

Analysis of Launch and Postapproval Cancer Drug Pricing, Clinical Benefit, and Policy Implications in the US and Europe

DOI: 10.1001/jamaoncol.2021.2026
JAMA Oncology, 2021, 7, e212026.

Source: <https://exaly.com/paper-pdf/82160856/citation-report.pdf>

Version: 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
29	Value-based pricing of drugs with multiple indications or in combinations - lessons from Europe. <i>Nature Reviews Clinical Oncology</i> , 2021 ,	19.4	2
28	Hochpreisigkeit bei Onkologika. 2021 , 79-92		6
27	Price trends of reimbursed oncological drugs in Switzerland in 2005-2019: A descriptive analysis. <i>PLoS ONE</i> , 2021 , 16, e0259936	3.7	0
26	Medicare Spending, Utilization, and Quality in the Oncology Care Model. <i>JAMA - Journal of the American Medical Association</i> , 2021 , 326, 1805-1806	27.4	1
25	Kosten-Nutzen-Bewertung von Arzneimitteln. 2021 , 57-66		1
24	Onkologika. 2021 , 579-638		
23	How value-based policy interventions influence price negotiations for new medicines: An experimental approach and initial evidence.. <i>Health Policy</i> , 2021 , 126, 112-112	3.2	
22	Price changes and within-class competition of cancer drugs in the USA and Europe: a comparative analysis.. <i>Lancet Oncology</i> , 2022 ,	21.7	2
21	Characteristics of oncology podcasts: Attitudes, speakers, conflicts.. <i>Journal of Cancer Policy</i> , 2022 , 32, 100329	1	1
20	Comparison of Cancer-Related Spending and Mortality Rates in the US vs 21 High-Income Countries. <i>JAMA Health Forum</i> , 2022 , 3, e221229	2	2
19	Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia. <i>JCO Oncology Practice</i> ,	2.3	2
18	Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China. <i>Pharmacoeconomics</i> , 2022 , 40, 715-724	4.4	1
17	Reforming Patient Cost Sharing for Cancer Medications in Medicare Part D.		
16	Kosten-Nutzen-Bewertung von Onkologika. 2022 , 25, 22-25		0
15	Cost-effectiveness of Response-Adapted De-escalation of Immunotherapy in Advanced Melanoma.		0
14	Barriers in access to oncology drugs in global crisis.		0
13	Comparison of Uptake and Prices of Biosimilars in the US, Germany, and Switzerland. 2022 , 5, e2244670		0

12	Were economic evaluations well reported for the newly listed oncology drugs in China's national reimbursement drug list. 2022 , 22,	o
11	Negotiating Drug Prices in the US—Lessons From Europe. 2022 , 3, e224801	o
10	Attribution of value for combination immune checkpoint inhibitors in non-small cell lung cancer. 2023 , 35, 100382	o
9	The price, efficacy, and safety of within-class targeted anticancer medicines between domestic and imported drugs in China: A comparative analysis. 2022 , 100670	o
8	Critical analysis of the prescription and evaluation of protein kinase inhibitors for oncology in Germany.	o
7	Hämatologische Neoplasien und solide Tumore. 2022 , 85-151	o
6	Assessment of FDA-Approved Drugs Not Recommended for Use or Reimbursement in Other Countries, 2017-2020. 2023 , 183, 290	o
5	Value assessment of NMPA-approved new cancer drugs for solid cancer in China, 2016–2020. 11,	o
4	Treatment patterns and out-of-hospital healthcare resource utilisation by patients with advanced cancer living with pain: An analysis from the Stop Cancer PAIN trial. 2023 , 18, e0282465	o
3	Out-of-Pocket Costs of Treatment Among Employer-Insured Women With Invasive Breast Cancer. 2023 , 6, e231507	o
2	Determinants of cancer drug pricing and how to overcome the cancer premium. 2023 , 186, 1528-1531	o
1	Financial Toxicity in Cancer Care: Implications for Clinical Care and Potential Practice Solutions.	o